October 31, 2023
BANGKOK — HOYA Vision Care is sharing one-year data from its MiYOSMART study that recently expanded into Europe.
With myopia increasing worldwide, there is a need to test the effectiveness of myopia management solutions in children of other ethnicities and geographic areas.1 To gather the needed data, the HOYA Global Medical Affairs team began conducting a three-year observational study in the United Kingdom (U.K.), with the goal of extending MiYOSMART benefits to European children with myopia. The study reached its one year milestone earlier this year, with the results officially presented at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Conference held April 23-27, in New Orleans.2
The study involves 128 children aged 5 to 15 recruited at three university centers in the U.K. All children were prescribed MiYOSMART spectacle lenses and their progress was followed, with the aim to evaluate the performance of MiYOSMART spectacle lenses in European children.2 The results from this study demonstrated similar effectiveness of MiYOSMART spectacle lenses between European and Asian children, particularly in children aged 8 to 13 years.2,3 Most children were symptom-free within one week, showing strong tolerability and acceptance.2
“Childhood myopia is a widespread global concern, and our unwavering commitment to fighting this issue through innovative solutions like MiYOSMART spectacle lenses is stronger than ever. The interim results of our European research are encouraging,” said Dr. Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care. “The comparable outcomes in the European cohort underscore that MiYOSMART represents an effective approach to slowing myopia progression in children, irrespective of their ethnicity. We look forward to sharing the results of this three-year study in the near future.”
Over two million parents across the world have already trusted MiYOSMART since its launch in 2018.4 With the MiYOSMART evidence extending to a European cohort, HOYA Vision Care will continue to help fight and control the growing problem of myopia around the world.
Product Disclaimer: MiYOSMART spectacle lenses have not been approved for use in the management of myopia in all countries, including the U.S., and are not currently available for sale in all countries, including the U.S.
References
- Grzybowski A, Kanclerz P, Tsubota K, Lanca C, Saw SM. A review on the epidemiology of myopia in school children worldwide. BMC Ophthalmol. 2020;20(1):27.
- McCullough S, Barr, H, Fulton, J, et al. 2-Year Multi-Site Observational Study of MiYOSMART myopia control spectacle lenses in UK children:1-year results (Abstract). ARVO 2023; 23-27 April 2023; New Orleans, LA, USA.
- Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020;104(3):363-8.
- Based on number of MiYOSMART spectacle lenses sold per HOYA sales data on file as of July 2023.
